Drug intelligence / Profile preview

COMP04

Development stage: Unknown
Lead developer: Promius Pharma, LLC

Overview

COMP04 is a code name for an investigational drug evaluated as part of a combination therapy in clinical trials for actinic keratosis. It was studied alongside other compounds (Comp01, Comp02, Comp03) and the topical agent ACT01 in patients with facial and/or scalp actinic keratosis. The specific active ingredient, mechanism of action, modality, or chemical class of COMP04 has not been disclosed in publicly available sources. Its use appears limited to research settings as part of multi-arm studies assessing efficacy and tolerability for dermatological conditions[2].

Beyond the preview

Go deeper on COMP04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMP04.

Explore the full profile